Merck KGaA, Darmstadt, Germany, a leading science and technology company, has adopted Quris’ Bio-AI clinical prediction platform as part of its drug development pipeline. Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA, Darmstadt, Germany, in which Quris-AI delivered a significantly higher accuracy in detecting drug-induced liver injury (DILI...